Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399001 | 1.00 | GPR119 (0.37) | GPR119JAK2JAK3PTK2PIK3CD | |
| SCHEMBL21797124 | 1.00 | GPR119 (0.37) | GPR119JAK2JAK3PTK2PIK3CD | |
| SCHEMBL21796987 | 0.91 | LRRK2 (0.38) | GPR119PIK3CDMAPTTP53PIK3CA | |
| SCHEMBL18398964 | 0.91 | LRRK2 (0.38) | GPR119PIK3CDMAPTTP53PIK3CA | |
| SCHEMBL21796989 | 0.91 | LRRK2 (0.38) | GPR119PIK3CDMAPTTP53PIK3CA | |
| SCHEMBL21796958 | 0.89 | LRRK2 (0.34) | — | |
| SCHEMBL21796591 | 0.80 | LRRK2 (0.41) | — | |
| SCHEMBL31433802 | 0.80 | GPR119 (0.41) | GPR119MAPT | |
| SCHEMBL20438215 | 0.79 | GPR119 (0.39) | GPR119JAK2JAK3PTK2PIK3CD | |
| SCHEMBL21796615 | 0.77 | GPR119 (0.40) | GPR119JAK2JAK3PTK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | GPR119 983/4885JAK2 853/4885JAK3 608/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | GPR119 1671/4885JAK2 2635/4885JAK3 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.